New Atypical Antipsychotics in the Treatment of Schizophrenia and Depression.

ABSTRACT: Schizophrenia and depression are heterogeneous disorders. The complex pathomechanism of the diseases imply that medication responses vary across patients. Many psychotropic drugs are available but achieving optimal therapeutic effect can be challenging. The evidence correlates well with clinical observations, suggesting that new atypical antipsychotic drugs are effective against negative and cognitive symptoms of schizophrenia, as well as against affective symptoms observed in depression. The purpose of this review presents the background and evidence for the use of the new second/third-generation antipsychotics (aripiprazole, cariprazine, lurasidone, asenapine, brexpiprazole, lumateperone, pimavanserin) in treatment of schizophrenia and depression. We have first provided a brief overview

SUBMITTER: Orzelska-Gorka J 

PROVIDER: S-EPMC9500595 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature